Piramal Pharma Ltd

NSE: PPLPHARMA · BSE: 543635 · Pharmaceuticals & Biotechnology · 32 announcements

Share price: ₹206.59
Market cap: ₹27,504 Cr
Revenue (annual): ₹8,869 Cr
Net profit (annual): ₹-325.9 Cr
P/E (TTM): -87.7×Sector 49.7×
Promoter holding: 34.80%-0.06% QoQ
FII holding: 12.51%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

Announcement type

All Business Update 7 Other Announcement 6 Financial Results 3 Share Pledge 2 Results Update 2 Regulatory Approval 2 Merger & Restructuring 2 Employee Stock Options 2 Annual General Meeting 2 Management Change 1 Earnings Call 1 Board Meeting Date 1 Adverse Business Impact 1

Time

All time Last 1 week Last 1 month Last 2 months Last 3 months Last 6 months Last 1 year

3 announcements with these filters

29 Jul 2026 20:45 IST NSE

Financial Results

Piramal Pharma Q1 FY27 Results: Net Loss of ₹69.4 Cr, Loss Narrows

Piramal Pharma Ltd reported revenue from operations of ₹2,270 Cr (+17.4% YoY) and a net loss of ₹69.4 Cr for Q1 FY27.

Key figure: Net loss ₹69.4 Cr

Open full results → Read the filing ↗

28 Apr 2026 21:10 IST BSE

Financial Results

Piramal Pharma Q4 FY26 Results: Net Loss of ₹8.8 Cr

Piramal Pharma Ltd reported revenue from operations of ₹2,752 Cr (-0.1% YoY) and a net loss of ₹8.8 Cr for Q4 FY26.

Key figure: Net loss ₹8.8 Cr

Open full results → Read the filing ↗

28 Apr 2026 21:09 IST BSE

Financial Results

Piramal Pharma Financial Results

Piramal Pharma Limited reported its FY2026 audited financial results, showing standalone annual revenue of ₹4,782.01 Crore and PAT of ₹700.01 Crore. The Board also approved the re-appointment of Ms. Nandini Piramal as Chairperson and Mr. Peter DeYoung as Executive Director, alongside shifting the company's registered office and appointing a new Company Secretary.

Read the filing ↗